Fenspiride
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.[2] The pharmacotherapeutic classification is antitussives. In Russia it is approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.[3]
Synthesis
Synthesis
The cyanohydrin of N-benzyl-4-piperidone is reduced with hydride to the aminoalcohol. This forms a cyclic carbamate on heating with diethyl carbonate. Hydrogenolysis of the N-benzyl group and alkylation of the liberated amino group with phenethyl chloride gives fenspiride.[4]
References
References
- ↑ Montes, B; Catalan, M; Roces, A; Jeanniot, JP; Honorato, JM (1993). “Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial”. European journal of clinical pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024.
- ↑ Płusa T, Nawacka D (Dec 1998). “Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections”. Pol Merkur Lekarski. 5 (30): 368–71. PMID 10101527.
- ↑ “Эреспал® (Eurespal®) Prescribing Information. VIDAL Drug Compendium” (in Russian). Retrieved 6 February 2014.
- ↑ NL 6504602
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH